The National Pharmaceutical Pricing Authority (NPPA) has told oncology drug manufacturers that they do not have to pull back, relabel or re-sticker cancer-drug packs that are already in the market when the new trade-margin-capped prices take effect, provided they make sure retailers actually charge the revised maximum retail price (MRP).

The clarification is part of a set of frequently asked questions (FAQs) the regulator has issued on its Trade Margin Rationalisation (TMR) order of 17 October 2026, which caps trade margins at 30% of MRP for 137 non-scheduled anti-cancer drugs. The revised prices come into force on 9 November 2026.

What the FAQs settle for manufacturers

The recall question was one of the biggest operational worries for companies, distributors and hospitals ahead of the switchover. In its response, NPPA said recalling, relabelling or re-stickering stocks released before the revised MRP is implemented “is not mandatory, if manufacturer is able to ensure price compliance at the retailer level”. That shifts the burden from physical repackaging to price communication down the supply chain.

The FAQs also spell out several compliance steps:

• Form V and Annexure-I: Manufacturers must file both through NPPA’s Integrated Pharmaceutical Database Management System (IPDMS) within seven days of the order’s publication, whether or not their MRP changes. NPPA said Annexure-I is now live on the portal.
• Newspaper notices: Companies must advertise every product whose price falls, listing both the pre-revised and the revised MRP. Products with no change may be included at the company’s choice.
• Patient Assistance Programmes: Undertakings relating to Patient Assistance Programmes (PAP) must be submitted by all manufacturers before 29 October 2026, and again whenever the MRP is revised.
• Scope: The margin cap applies to every strength, dosage form and combination containing any of the listed molecules, even when the formulation is used for a non-cancer indication.
• Government supplies: Sales count as government sales only when no MRP is printed on the pack, or when the pack is clearly labelled “For supply to Government; not for sale”.
• Net-sales calculation: Sales returns cannot be adjusted while calculating net sales for price-to-stockist and price-to-distributor figures.

At the request of industry associations, NPPA has also given companies until 9 November 2026 to submit certain additional information required under the order. Separately, reports note that the regulator has confirmed manufacturers can still use the annual price increase of up to 10% that the Drugs (Prices Control) Order, 2013 allows for non-scheduled formulations.

Why it matters

The TMR order covers widely used oncology therapies, including immunotherapies such as pembrolizumab and durvalumab, targeted drugs such as osimertinib, and supportive-care biologics such as denosumab, pegfilgrastim and bevacizumab. The government expects MRPs of the listed drugs to fall by up to 70% depending on existing price structures, and has estimated patient savings of about ₹2,500 crore a year. It builds on NPPA’s 2019 pilot, when margins on 42 anti-cancer drugs were capped at 30% and MRPs of 526 brands fell by up to 90%.

Not having to recall stock removes a significant cost and logistics burden for manufacturers and distributors during the transition. The trade-off is enforcement: with older packs still carrying the higher printed price, companies will need to show that retailers and hospitals are billing at the revised rate. Under the order, they must publish price lists on their websites, circulate them to dealers and retailers, and be ready to give NPPA batch-wise production and stock details on demand. Retailers and hospitals must display the revised prices, and patients can check them on the Pharma Sahi Daam app and the NPPA website.

The guidance comes as drug pricing is under close scrutiny. On 27 October the Supreme Court, while reserving its order on petitions over high medicine prices, questioned the gap between MRP and the price at which drugs reach retailers, and noted that the cancer-drug margin cap came only after the court stepped in.

For India’s pharma industry, the TMR rollout is a live test of how pricing, supply-chain compliance and patient access come together. These are issues that will feature strongly in industry conversations at India Pharma Expo 2027 and the NextGen Pharma Summit.

Image credit: Photo: Bill Branson / National Cancer Institute, via Wikimedia Commons (public domain), “Chemotherapy vials” — https://commons.wikimedia.org/wiki/File:Chemotherapy_vials_(4).jpg (cropped; representative image)

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!